![Frank P. Holladay](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Frank P.
Holladay is the founder of TVAX Biomedical I LLC and TVAX Biomedical, Inc. He held the title of Chief Medical Officer at both companies, which were founded in 2004 and 2011, respectively.
Holladay received a doctorate degree from Creighton University and an undergraduate degree from the University of California, Berkeley.
Actieve functies van Frank P. Holladay
| Bedrijven | Functie | Begin |
|---|---|---|
| TVAX BIOM | Oprichter | 14-07-2011 |
TVAX Biomedical I LLC
 TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004. | Oprichter | 01-11-2004 |
Opleiding van Frank P. Holladay
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
14
Eerstegraads connecties
4
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
TVAX Biomedical, Inc.
 TVAX Biomedical, Inc. BiotechnologyHealth Technology Manufactures and sells healthcare products | Health Technology |
Creighton University
 Creighton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Berkeley
 University of California, Berkeley Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
TVAX Biomedical I LLC
TVAX Biomedical I LLC Part of TVAX Biomedical, Inc., TVAX Biomedical I LLC is a clinical stage development company based in Lenexa, KS. TVAX Biomedical I LLC specializes in the development of a novel targeted cell-based immunotherapy for the treatment of cancer. The company's immunotherapeutic cancer treatment platform is based on over 50 years of scientific and medical research into the interactions between cancer and the immune system. TVAX Immunotherapy employs the natural ability of T cells to kill cancer cells and has demonstrated the ability to effectively treat numerous cancers without many of the undesirable side effects associated with radiation and chemotherapy. The key difference between TVAX Biomedical I LLC and other cancer immunotherapy companies is that it uses both cancer vaccine pretreatment to generate cancer-specific T cells and activated "killer" T cell treatment, which has demonstrated significant efficacy. The proprietary treatment has received orphan product designation from the FDA for the prevention and treatment of any primary central nervous system malignancy, providing the company with seven years of marketing exclusivity following FDA marketing approval. The company was founded by Catherine E. Lucasey, Frank P. Holladay, Gray W. Wood. Gray W. Wood has been the CEO of the company since 2004. |
